Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049303 | 0.91 | GABRP (0.42) | LMNADRD2KCNH2HRH3FFAR1 | |
| SCHEMBL5886646 | 0.80 | KCNH2 (0.55) | LMNADRD2KCNH2FFAR1FFAR4 | |
| SCHEMBL6304808 | 0.80 | GABRP (0.47) | LMNADRD2KCNH2HRH3FFAR1 | |
| SCHEMBL6777687 | 0.79 | CYP1A2 (0.50) | LMNAHRH3FFAR1FFAR4 | |
| SCHEMBL6796098 | 0.78 | KDM4E (0.46) | LMNADRD2KCNH2HRH3FFAR1 | |
| SCHEMBL11461630 | 0.77 | KCNH2 (0.45) | LMNADRD2KCNH2FFAR1FFAR4 | |
| SCHEMBL5886641 | 0.77 | KCNH2 (0.60) | LMNAKCNH2FFAR1FFAR4TNK2 | |
| SCHEMBL9247329 | 0.76 | KCNH2 (0.51) | LMNADRD2KCNH2FFAR1FFAR4 | |
| SCHEMBL9663162 | 0.75 | LMNA (0.43) | LMNADRD2KCNH2HRH3 | |
| SCHEMBL9248307 | 0.74 | KCNH2 (0.54) | LMNADRD2KCNH2FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949661-B2 | 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-6861445-B2 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6784184-B2 | FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES | WYETH HOLDINGS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-6740675-B2 | ANTICANCER THERAPY | WYETH HOLDINGS CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20040063971-A1 | 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040063777-A1 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-6605628-B1 | Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis | WYETH HOLDINGS CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY | 2003-08-07 | — | — | US | disclosed |
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY (US) | 2003-07-31 | — | — | US | disclosed |
| US-20030083364-A1 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrroldine-2,5-diones useful for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY | 2003-05-01 | — | — | US | disclosed |
| WO-2003018554-A1 | 3-SUBSTITUTED-3-(SUBSTITUTEDSULFONYL OR SULFANYL)PYRROLIDINE-2,5-DIONES USEFUL FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE | WYETH HOLDINGS CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003018135-A1 | METHOD OF USING 5-(ARYLSULFONYL)-,5-(ARYLSULFINYL), AND 5-(ARYLSULFANYL)-THIAZOLIDINE-2,4-DIONES FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE | WYETH HOLDINGS CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | FNTB, FNTA, TST | LMNA 4485/4885DRD2 4082/4885KCNH2 4716/4885 |
| US-20040063777-A1 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | FNTA, FNTB, FDPS | LMNA 4161/4885DRD2 4757/4885KCNH2 4743/4885 |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | FNTB, FNTA, NAT1 | LMNA 4390/4885DRD2 3921/4885KCNH2 4762/4885 |
| US-20030083364-A1 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrroldine-2,5-diones useful for inhibition of farnesyl-protein transferase | FNTA, FNTB, FDPS | LMNA 4125/4885DRD2 4675/4885KCNH2 4763/4885 |
| US-20040063971-A1 | 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | FNTA, FNTB, FDPS | LMNA 4161/4885DRD2 4757/4885KCNH2 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.